Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome

Exclusion Criteria

• •Participants with newly diagnosed medical condition requiring intervention that has not been stabilized at least 30 days prior to Baseline.
• •Participants with a significant medical condition that require intervention during the course of study participation (such as anticipated major elective surgery).
• •Participants with an unstable medical condition (including, but not limited to, uncontrolled hypertension, epilepsy requiring anti-epileptic medicine, unstable angina, confirmed inflammatory bowel disease, hyperprolactinemia, clinically significant infection or injury).